Neuren Pharmaceuticals (ASX:NEU) Institutional Ownership: 26.41% (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NEU Neuren Pharmaceuticals Ltd ASX:NEU
49 GF Score
Price A$16.97
GF Value A$7.25
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals Institutional Ownership?

Neuren Pharmaceuticals ASX:NEU -3.08% 49 Institutional Ownership is 26.41% as of Jul. 19, 2026. GuruFocus rates ASX:NEU with a GF Score™ of 49/100 and a GF Value™ of A$7.25 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Neuren Pharmaceuticals's institutional ownership is 26.41%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Neuren Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Neuren Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Neuren Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals Institutional Ownership Chart

Neuren Pharmaceuticals Historical Data

The historical data trend for Neuren Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 24.08 23.13 23.78 25.10 25.29 25.66 25.27 25.71 26.36 26.41
ASX:NEU
49GF Score
Neuren Pharmaceuticals Ltd ASX:NEU
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 26.41% mean?
Neuren Pharmaceuticals (ASX:NEU) has a Institutional Ownership of 26.41% as of Jul. 19, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Neuren Pharmaceuticals and its competitors.
Is Neuren Pharmaceuticals' Institutional Ownership too high?
Neuren Pharmaceuticals' current Institutional Ownership is 26.41%. Overall, Neuren Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Institutional Ownership compare to VRTX and REGN?
Neuren Pharmaceuticals' Institutional Ownership of 26.41% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Institutional Ownership is 26.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.25, compared to a current price of A$16.97 — trading 134.1% above its estimated fair value. The current Institutional Ownership is 26.41%. Neuren Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Institutional Ownership is 26.41% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of A$16.97 is trading 134.1% above its estimated GF Value™ of A$7.25. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:NEU:

  • Institutional Ownership: 26.41%
  • GF Value™: A$7.25 vs. price of A$16.97 (134.1% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANK9:Germany
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
49GF Score

Get the complete analysis for ASX:NEU

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$16.97
Price
A$7.25
GF Value